The interferon-regulated 2-5A/RNase L pathway plays a major role in the antiviral and antiproliferative activities of these cytokines. Several viruses, however, have evolved strategies to escape the antiviral activity of the 2-5A/RNase L pathway. In this context, we have cloned a cDNA coding for the RNase L inhibitor (RLI), a protein that specifically inhibits RNase L and whose regulated expression in picornavirus-infected cells down regulates the activity of the 2-5A/RNase L pathway. We show here that RLI increases during the course of human immunodeficiency virus type 1 (HIV-1) infection, which may be related to the downregulation of RNase L activity that has been described to occur in HIV-infected cells. In order to establish a possible causal relationship between these observations, we have stably transfected H9 cells with RLI sense or antisense cDNAexpressing vectors.
Interferons (IFN) control various cellular functions and participate in host defense against viral and microbial agents through multiple induced pathways (1) . The 2-5A/RNase L pathway is one of the major pathways induced by IFN. It is implicated in some of the antiviral mechanisms of IFN and might play a role in the regulation of RNA turnover and stability (12) . IFN induces four different forms of human 2-5A-synthetase which, upon activation by double-stranded RNA (dsRNA), convert ATP into an unusual series of oligomers known as 2-5A. 2-5A then activates RNase L, a latent endoribonuclease, which inhibits protein synthesis by cleavage of mRNA at the 3Ј side of UpNp sequences (11, 13, 40) . During viral infection this antiviral pathway can be activated, since several viruses produce dsRNA structures that can activate 2-5A-synthetase. The presence of 2-5A has been demonstrated in cells infected with encephalomyocarditis (EMC) virus (38) , vaccinia virus (22) , or reovirus (19) .
Although 2-5A has long been considered to be the unique regulator of the 2-5A/RNase L pathway, we have cloned and characterized a polypeptide inhibitor of the 2-5A pathway (referred to as RNase L inhibitor [RLI] ). RLI cDNA codes for a 68-kDa protein whose mRNA is not regulated by IFN. When expressed in a reticulocyte lysate, RLI induces neither 2-5A degradation nor irreversible modification of RNase L (3); however, it antagonizes the binding of 2-5A by the latter and thus its nuclease activity, since 2-5A binding is a prerequisite to RNase L dimerization and activation (10, 31) .
Despite the presence of double-stranded viral RNA structures capable of activating the 2-5A/RNase L pathway and the presence of high concentrations of 2-5A, in several cases no RNase L activity could be detected. Several viruses appear to have developed strategies to counteract the antiviral activity of the 2-5A/RNase L pathway. For example, during herpes simplex virus type 1 and 2 (HSV-1 and HSV-2) infection, 2-5A derivatives are synthesized that behave as 2-5A antagonists (7) . Similarly, infection by vaccinia virus leads to an inhibition of 2-5A-synthetase activity and to the degradation of 2-5A (20) . Recently, Rivas et al. have shown that vaccinia virus E3L protein is an inhibitor of 2-5A-synthetase (23) . Finally, EMC virus downregulates RNase L activity through the increased expression of RLI (18) .
Along the same lines, an inhibition of RNase L activity has been observed during the course of human immunodeficiency virus (HIV) infection. RNase L is inactive in peripheral blood mononuclear cell extracts from AIDS patients, despite the presence of its 2-5A activator (5) . Likewise, the 2-5A binding activity of RNase L in lymphocytes isolated from AIDS and pre-AIDS patients was approximately 65% lower than that found in controls (39) . In experimental infection of H9 cells with HIV type 1 (HIV-1), a strong enhancement of 2-5A-synthetase activity and a small increase of RNase L activity were observed. Both enzymes reached maximal levels at day 3 after the onset of HIV-1 infection and declined sharply thereafter. Interestingly, RNase L can degrade HIV-1 transcripts during the early steps of infection, and HIV-1 transcript accumulation coincides with the decrease of RNase L activity (29, 35) . These studies suggest that there is an accumulation of an inhibitor of the 2-5A/RNase L pathway that interferes with 2-5A binding through the formation of an inhibitor-RNase L complex. On the other hand, different studies have suggested that direct expression or activation of the 2-5A/RNase L pathway enzymes can lead to suppression of HIV replication. For example, the stable expression of transfected 2-5A-synthetase leads to the suppression of HIV replication (27, 28) . Direct activation of RNase L with phosphorothioate-phosphodiester 2-5A derivatives inhibits HIV-1 reverse transcriptase and HIVinduced syncytium formation (33) . Recently, Maitra and Silverman have shown that overexpression of RNase L can suppress HIV-1 replication (17) . These results show that the 2-5A/ RNase L pathway is potentially able to regulate HIV replication but is rapidly inhibited after the early stages of HIV infection.
RLI is a logical candidate to be the inhibitor induced by HIV infection. We have therefore studied the modulation of RNase L and RLI expression in H9 cells following HIV-1 infection. We have established that if RNase L activity decreased during the course of HIV-1 infection, the RNase L protein decreases only transiently and the amount of RLI protein increases. We have stably transfected H9 cells with RLI sense or antisense cDNA-expressing vectors and followed the course of de novo HIV-1 infection in two independent RLI sense clones and two independent RLI antisense clones. As expected, the overexpression of RLI decreases RNase L activity and enhances HIV-1 production while, on the contrary, the reduction of the RLI level correlates with an increase in RNase L activity and a decrease in virus production. Altogether, these data suggest that RLI could be a cellular inhibitor induced by HIV-1 to inhibit the 2-5A/RNase L pathway.
MATERIALS AND METHODS
Cells and virus. H9 cells (human T lymphocyte cell line) were grown in RPMI Glutamax medium (Gibco BRL) supplemented with 10% (vol/vol) fetal calf serum. Strain IIIB of HIV-1 was grown in H9 cells and titrated by a reverse transcriptase (RT) assay (21) .
For HIV-1 infection, H9 cells (3 ϫ 10 8 ) were centrifuged and the cell pellet was resuspended in 150 ml with HIV-1 strain IIIB corresponding to 4.5 ϫ 10 6 cpm of RT activity (15, 16) . After 1 h of incubation at 37°C, the cells were seeded at a final concentration of 2 ϫ 10 5 cells per ml in RPMI Glutamax containing 10% (vol/vol) fetal calf serum.
Expression vectors and transfections. The human RLI cDNA (3) was subcloned in the sense or antisense orientation in pcDNA3 (Invitrogen) by standard procedures (26) . Then, 5 ϫ 10 5 H9 cells were transfected by electroporation (250 mV) with 10 g of plasmid DNA. The empty pcDNA3 vector was used as a control. Stable transfectants were selected by culturing the cells in the presence of 1 mg of G418 (Gibco BRL) per ml. Individual clones were isolated by limit dilution and analyzed for the expression of the transfected cDNA. Clones expressing the transfected antisense cDNA were named VAS1 and VAS2; clones expressing the transfected sense cDNA were named VS1 and VS2, and the clone expressing the transfected empty vector was named VV.
Cell extracts. After infection, cells were collected at the times indicated and were resuspended in 1 volume of hypotonic buffer (0.5% [vol/vol] Nonidet P-40, 20 mM HEPES [pH 7.5], 10 mM potassium acetate, 15 mM magnesium acetate, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, 10 g of aprotinin per ml, 150 g of leupeptin per ml), disrupted in a Dounce homogenizer, and centrifuged at 10,000 ϫ g as described previously (25) . The supernatant (S10) was pipetted off, and its protein concentration was determined by spectrophotometry (37) .
Western blot analysis. Cell extracts were analyzed by Western blot according to the method of Towbin et al. (34) . Proteins were fractionated by sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and transferred electrophoretically to a nitrocellulose membrane. For antibody revelation, the nitrocellulose membrane was soaked for 1 h in phosphate-buffered saline (PBS) (140 mM NaCl-2 mM KCl-8 mM Na 2 HPO 4 -1.5 mM KH 2 PO 4 supplemented with 5% [wt/vol] skim milk) and then held overnight at 4°C with the polyclonal antibodies against RNase L (1/1,000) or RLI (1/500) that we have previously described and characterized (18) or with anti-gp120 (1/100) (a generous gift of D. Misse, ORSTOM, Montpellier, France) or anti-GAPDH (1/3,000) (a generous gift of G. Cathala, IGM, Montpellier, France) in the same buffer. The filter was washed with PBS supplemented with 0.05% (vol/vol) Tween 20 and incubated for 1 h at room temperature with donkey anti-rabbit immunoglobulin antibody conjugated to horseradish peroxidase (1/2,000; Amersham) in PBS supplemented with 5% (wt/vol) skim milk. Chemiluminescence was generated by the NEN kit. The gels were scanned, and the protein bands were quantified by image analysis with the Intelligent Quantifier program (BioImage Systems Corp.). Results are expressed as an average of three independent experiments. Standard deviations are indicated by vertical bars in the figures.
2-5A binding activity of RNase L during infection of cells with HIV-1. H9 cells, as well as the VV, VS, and VAS transfectants (3 ϫ 10 8 cells), were infected with HIV-1 (4.5 ϫ 10 6 cpm of RT activity) (15, 16) . Cells were harvested at various times after the onset of infection as indicated. Cell extracts (S10) were prepared as described above. The radiobinding assay (14) was performed with S10 cell extracts (600 g of proteins) as a source of RNase L and 2-5A 4 -3Ј-[
32 P]pCp (2-5ApCp) (20,000 cpm, 3,000 Ci/mmol) as a probe. The radiobinding assay was utilized with the modifications previously described (2, 4) . Results are expressed as an average of three independent experiments for each cell clone (H9, VV, VS1, VS2, VAS1, and VAS2). Standard deviations are indicated by vertical bars.
RNA analysis. Total cellular RNA was prepared by using the guanidine thiocyanate-lithium chloride procedure (6) . Northern blot hybridizations were performed according to standard techniques (26 
RESULTS

RNase L activity decreases in HIV-1-infected cells.
The nuclease activity of RNase L is strictly dependent on its activation by 2-5A (31), so we measured the RNase L activity in HIV-1-infected H9 cells with the 2-5A radiobinding assay (14) . This assay quantifies the binding of a radioactive 2-5ApCp probe to RNase L in unfractionated cell extracts. In keeping with the data described in the introduction, we observed a decrease in the binding of 2-5ApCp by RNase L in extracts from HIV-1-infected H9 cells. 2-5A binding decreases by as early as 3 days after the onset of HIV-1 infection and reaches a minimum 10 days after the onset of HIV-1 infection (Fig. 1A) . The virus production was monitored by Western blot analyses of the HIV-1 gp120 polypeptides in cell extracts. The polyclonal antibody against gp120 we have used also recognizes its gp160 precursor. gp120-gp160 polypeptides could be detected at day 3 postinfection and reached maximal levels at days 7 and 8 (Fig. 1B) .
The decrease of RNase L activity monitored by the 2-5A radiobinding assay in unfractionated cell extracts could result from a decrease in RNase L itself or from the induction of an inhibitor. Polyclonal antibodies against RNase L and RLI have been used to quantify RNase L and RLI during the course of HIV-1 infection.
RLI increases during HIV-1 infection. RNase L was quantified by a Western blot assay with the RNase L-specific polyclonal antibody described previously (18) . RNase L was detected at all time points, decreasing transiently (by 40%) between days 4 and 6 ( Fig. 2) and then increasing. The decrease of RNase L activity observed in cell extracts during the time course of HIV-1 infection (Fig. 1) coincides with the increased protein level, particularly between days 6 and 9, suggesting that there is the accumulation of an inhibitor. Since RLI inhibits the binding of 2-5ApCp to RNase L (3), it is a logical candidate for this role and, indeed, it increases during the time course of HIV-1 infection (Fig. 2) Fig. 2A) . The stable transfection of an RLI antisense or RLI sense construction modifies RNase L activity during HIV-1 infection. To determine the effects of regulating RLI levels on HIV-1 infection, H9 cells were stably transfected with RLI constructions in either the sense or the antisense orientation. H9 cell transfected clones were characterized by a Western blot assay with a polyclonal antibody against RLI protein (Fig.  3A) and with the 2-5ApCp binding activity of RNase L (Fig.  3B) . Clones expressing the RLI antisense construction, the RLI sense construction, and the empty vector have been named VAS, VS, and VV, respectively. Two independent clones expressing higher levels of RLI (VS1 and VS2) demonstrated lower 2-5A binding activity by RNase L than cells transfected with the empty vector. On the contrary, in two independent clones expressing lower levels of RLI (VAS1 and VAS2), the 2-5A binding activity of RNase L is increased (Fig. 3B) .
The 2-5A binding activity of RNase L during HIV-1 infection was analyzed in these clones expressing different levels of RLI (Fig. 4) . HIV-1 infection of the VV clone gives rise to a 68% decrease in RNase L activity, a result in line with the data presented in Fig. 1 for the nontransfected H9 cells. A significantly larger decrease in RNase L activity is observed in the clones expressing the RLI sense construction: 90% for VS1 and 95% for VS2 (Fig. 4A and B) . On the other hand, the clones expressing the RLI antisense construction lead to a much lower inhibition of RNase L activity: 29% for VAS1 and 22% for VAS2 (Fig. 4) upon HIV-1 infection. As expected, therefore, overexpression of RLI increases the HIV-1-associated down regulation of RNase L activity, and lower expression of RLI antagonizes the HIV-1-associated down regulation of RNase L activity.
The production of HIV is proportional to the RLI level. The RLI protein level modulates RNase L activity. We therefore analyzed whether the replication of HIV-1 is modified in the different transfectants. Virus production was monitored by different techniques: the measurement of RT activity in the cell culture supernatant, Northern blot analysis of HIV mRNA transcripts, and Western blot analysis of the HIV-1 gp160/ gp120 polypeptides in cell extracts.
As clearly shown in Fig. 5 , the clones expressing the RLI sense constructions (VS1 and VS2) produced significantly larger amounts of virus than did the control cells, as monitored by the RT activity peak. On the contrary, the RT activity was highly repressed (by 75%) in the clones expressing the RLI antisense construction (VAS1 and VAS2) (Fig. 5) .
The mechanism of the pro-HIV effect of overexpressing RLI was then investigated by detection of the total levels of the (Fig. 6A) .
This difference in HIV-1 RT activity and mRNA was also observed at the protein level.
The amount of the HIV-1 gp160/gp120 proteins was evaluated by Western blot assays with a polyclonal antibody. In the VV clone, gp160/gp120 polypeptides could be detected as early as 3 days postinfection and reached maximal levels at days 5 and 6 (Fig. 6B) . The high RT activity in the VS2 clone was correlated with the presence of gp160/gp120 as early as 2 days after the onset of infection; the amount of both proteins increased to maximum levels at days 4, 5, and 6. On the other hand, gp160/gp120 polypeptides were poorly expressed in the VAS2 clone and were absent from day 7 (Fig. 6B) .
DISCUSSION
HIV replication decreases when RLI is underexpressed in human cells. We show here that RLI can be a suppressor of HIV replication when it is underexpressed in human H9 cells by transfection with an RLI antisense cDNA construction. On the contrary, when RLI is overexpressed in human H9 cells transfected with an RLI sense construction, HIV replication is greatly increased.
The strategy we used here bypasses the requirement for IFN treatment to obtain inhibition of viral growth. This strategy has been used with success in different systems to study the role of several IFN-inducible proteins, and it has revealed the importance of these proteins in the antiviral action of IFN. Moreover, this strategy has overcome problems associated with viruses that have developed powerful tools to block specific IFN pathways. Indeed, as outlined in the introduction, during the course of a number of viral infections RNase L activity is not detectable, despite high levels of 2-5A-synthetase, 2-5A, or even RNase L (see reference 32 for a review). These observations provided strong evidence that viruses can inactivate the 2-5A/RNase L pathway. For example, the expression of 2-5A synthetase and/or RNase L in mouse cells restores apoptosis inhibited by the vaccinia virus E3L protein (23) and inhibits replication of EMC virus (8, 9, 24, 32, 36) . Similarly, we have previously demonstrated that when RLI expression is decreased in HeLa cells by transfected antisense RLI cDNA constructions, RNase L activity is increased during EMC virus infection and EMC virus production is lower (18) . HIV inhibits the 2-5A/RNase L pathway during the time course of infection (29, 30) ; similarly, expression of 2-5A-synthetase cDNA from an HIV-1 LTR reduced HIV replication in HeLa T4
ϩ cells (27, 28) . The overexpression of RNase L in Jurkat cells and in peripheral blood lymphocytes severely impairs HIV replication (17) . It is worth noting that the expression of RNase L in the different systems cited above seems to produce a much greater antiviral effect than did the expression of 2-5A-synthetase (17, 23) . Levels of RNase L represent a central limiting component to the antiviral activity of the 2-5A/ RNase L pathway.
RNase L activity is correlated with RLI levels in HIV-1-infected human cells. In the present report evidence is presented that modifying the RLI levels consequently gives rise to different levels of RNase L activity in HIV-1-infected cells and also affects viral production ( Fig. 3 and 4) .
Western blot assays with antibodies against RNase L and RLI reveal that the amount of RNase L is only transiently decreased upon HIV-1 infection and that RLI is simultaneously induced (Fig. 2) . We provide evidence here that the loss of RNase L activity during HIV-1 infection is due not only to a decrease in the level of the RNase L protein itself but also to the accumulation of the RNase L inhibitor, RLI. We have already established that the ratio between RNase L and RLI in cell extracts governs the overall activity of the 2-5A/RNase L system, even when 2-5A is present at doses largely sufficient to activate RNase L (3). When RLI is decreased by the expression of an RLI antisense cDNA construction, the antiviral activity of RNase L against EMC virus is increased (18) . These experiments demonstrate that slight changes in the ratio be- tween these two proteins could profoundly modify the 2-5A binding activity of RNase L. The increased RLI level observed here is sufficient to account for the inhibition of RNase L activity observed during HIV-1 infection. Moreover, the experiments described so far indicate a correlation among HIV-1 infection, the reversible inactivation of RNase L, and RLI induction. Modifying the level of expression of RLI through the expression of antisense or sense constructions represents an attractive possibility to substantiate this hypothesis. The inhibition of RNase L activity by HIV-1 varies in function of the amount of RLI (Fig. 4) . The overexpression of RLI giving rise to greater inhibition of RNase L activity correlated with a higher viral production. On the contrary, blocking of RLI by antisense construction reverses the inhibition of RNase L activity observed during HIV-1 infection and, consequently, inhibits viral production. These results are clearly illustrated in Fig. 5 and 6 . We could observe a great difference between the VAS and VS clones in the production of HIV-1 at both the mRNA and protein levels.
The 2-5A/RNase L pathway is a major component of the antiviral activity of IFN. Viruses have developed numerous strategies to circumvent this pathway. Many of these viral inhibitors are now being identified, though their presence was first described several years ago (see reference 32 for a review). RLI, the RNase L inhibitor that we have cloned and identified, is implicated in the inhibition of the 2-5A/RNase L pathway by EMC virus (3, 18) . The present study describes a new strategy that HIV-1 has evolved to inhibit cellular antiviral defenses. The identification of the antagonistic pathways developed by viruses is important in understanding the physiopathology of viral infection and in the implementation of new and more efficient antiviral strategies. In particular, it would be of interest to understand how HIV-1 is able to induce RLI and to inhibit the cellular antiviral defenses.
